

Date: 13.02.2017

To,  
Listing Department,  
Dept. of Corporate Services,  
Bombay Stock Exchange Limited,  
P.J. Towers, Dalal Street, Fort,  
Mumbai: 400 001.

To,  
General Manager,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E),  
Mumbai: 400 051.

Dear Sir/Madam,

Ref.:- Scrip Code - 532908

Scrip ID-SHARONBIO

Sub: - Outcome of the Board Meeting held on Monday, February 13, 2017.

This is with reference to meeting of the Board of Directors of the company held on Monday, February 13, 2017, we wish to intimate our esteemed exchanges that Board of Directors has:


- Approved and taken on record the Standalone Unaudited Financial Results of the Company for the quarter and nine months ended **December 31, 2016** along with the Limited Review Report thereon.

The Board Meeting commenced at 2:00 pm and concluded at 4:30 pm.

Kindly find the attached document for your record & acknowledge the receipt for the same.

Thanking You,

Yours faithfully,  
For **Sharon Bio-Medicine Limited**



Mrs. Savita Gowda  
Managing Director  
DIN: 00042957

Encl: a/a

Adm. Off. : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705.  
Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001  
[www.sharonbio.com](http://www.sharonbio.com)

CIN NO. L24110MH1989PLC052251

*Caring for relationships*



**EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2016.**

(₹ in Lacs)				
SR. NO.	PARTICULARS	Quarter Ended 31/12/2016	Nine Months Ended 31/12/2016	Corresponding Quarter Ended 31/12/2015
		(Un-Audited)	(Un-Audited)	(Un-Audited)
1	Total Income from Operations (net)	3,162.88	11,423.93	10,469.16
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(1,044.06)	(18,546.96)	(1,867.83)
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(2,617.78)	(32,603.75)	(6,817.36)
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	(2,617.78)	(32,603.75)	(6,817.36)
5	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	(2,617.78)	(32,603.75)	(6,817.36)
6	Paid-up Equity Share Capital (Face value of Rs.2/- each)	2,378.71	2,378.71	2,378.71
7	Earnings Per Share (of Rs.2/- each) (for continuing and discontinued operations) (not annualised)			
	a) Basic (in Rs.)	(2.20)	(27.41)	(5.73)
	b) Diluted (in Rs.)	(2.15)	(26.79)	(5.60)

Notes:

- The above results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on February 13, 2017.
- The Statutory Auditors of the Company has carried out the Limited Review of the above standalone results.
- The above is an extract of the detailed format of the Standalone Financial Results for the period ended December 31, 2016 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of these Financial Results are available on the Stock Exchange website, [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com), and on the Company's website [www.sharonbio.com](http://www.sharonbio.com).

**For Sharon Bio-Medicine Ltd.**

**SD/-**

**Savita Gowda**

**Managing Director.**

**Place : Mumbai.**  
**Date : 13.02.2017**

**REGISTERED OFFICE & WORKS : W-34 & 34/1, MIDC, Talaja,  
Dist.Raigad, Maharashtra (India).**

**CORP.: C-310/312, BSEL Tech Park, Opp. Vashi-Railway Station, Navi Mumbai – 400 703.**

**E-mail : [investor\\_complaints@sharonbio.com](mailto:investor_complaints@sharonbio.com), Website : [www.sharonbio.com](http://www.sharonbio.com)**